Cotización Lucid Diagnostics - LUCD

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

0.999

Postura de Compra

0.9876

Postura de Venta

1.06

Volume Operado de la Acción

315,753

0.98 Rango del Día 1.02

0.6301 Rango de 52 semanas 1.58

Capitalización de Mercado [m]

59.283M

Precio Anterior

1.00

Precio de Apertura

1.00

Hora

1.03

Última hora de negociación

Volumen financiero

US$ 315,723

Precio Promedio Ponderado

0.999906

Volumen promedio (3 m)

295,676

Acciones en circulación

59,342,479

Rendimiento del Dividendo

Ratio Precio/Utilidad

-1.13

Beneficio por acción (BPA)

-0.89

turnover

2.43M

Beneficio neto

-52.67M

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Mostrar más

Sector

Surgical,med Instr,apparatus

Industria

Surgical,med Instr,apparatus

Sede

Wilmington, Delaware, USA

Fundado

Lucid Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LUCD. The last closing price for Lucid Diagnostics was US$1. Over the last year, Lucid Diagnostics shares have traded in a share price range of US$ 0.6301 to US$ 1.58.

Lucid Diagnostics currently has 59,342,479 shares in issue. The market capitalisation of Lucid Diagnostics is US$59.34 million. Lucid Diagnostics has a price to earnings ratio (PE ratio) of -1.13.

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...

Form 8-K - Current report

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...

Form 8-K - Current report

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 13, 2024 EsoGuard® revenue up 20 percent sequentially Clinical evidence package for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.0368	-3.55280942267	1.0358	1.04	0.9029	598463	0.98143943	CS
4	0.149	17.5294117647	0.85	1.12	0.8456	508733	0.99204631	CS
12	0.2002	25.0625938908	0.7988	1.12	0.73	295676	0.91967317	CS
26	0.079	8.58695652174	0.92	1.12	0.681	224660	0.88082319	CS
52	-0.301	-23.1538461538	1.3	1.58	0.6301	182322	0.94228395	CS
156	-8.681	-89.6797520661	9.68	9.68	0.6301	131532	1.98751874	CS
260	-11.751	-92.1647058824	12.75	13.5	0.6301	140508	2.79829123	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WORXSCWorx Corporation	US$ 2.12 (116.33%)	144.38M
CRNCCerence Inc	US$ 5.83 (106.74%)	77.55M
PROCProcaps Group SA	US$ 1.10 (92.48%)	2.58M
IBGInnovation Beverage Group Limited	US$ 1.19 (50.40%)	12.97M
ARQQArqit Quantum Inc	US$ 10.7599 (46.59%)	900.38k
SKKSKK Holdings Limited	US$ 1.01 (-77.85%)	40.45M
TMTCTMT Acquisition Corporation	US$ 2.20 (-65.84%)	530.14k
WCTWellchange Holdings Company Limited	US$ 1.2596 (-62.06%)	2.34M
TMTCUTMT Acquisition Corporation	US$ 2.89 (-56.74%)	14.07k
GLXGGalaxy Payroll Group Ltd	US$ 1.77 (-54.73%)	2.45M
CDTConduit Pharmaceuticals Inc	US$ 0.1048 (13.54%)	579M
NVDANVIDIA Corporation	US$ 146.67 (0.53%)	401.66M
ELABElevai Labs Inc	US$ 0.020072 (-6.21%)	256.24M
AKTSAkoustis Technologies Inc	US$ 0.1022 (17.34%)	211.19M
MARAMARA Holdings Inc	US$ 24.19 (6.89%)	166.43M